Latest Biochemistry of Alzheimer's disease Stories
UCLA chemists and molecular biologists have for the first time used a "structure-based" approach to drug design to identify compounds with the potential to delay or treat Alzheimer's disease, and possibly Parkinson's, Lou Gehrig's disease and other degenerative disorders.
Researchers have found that the brains of patients with early-onset Alzheimer's produce about 20 percent more of a protein fragment known as amyloid beta 42 than family members without the disease.
Australian researchers have reported significant progress in developing a biomarker blood test that can predict the onset of Alzheimer’s in an individual as much as 17 years before symptoms appear.
The Journal of Neuroscience has published a study led by researchers at the Max Planck Florida Institute for Neuroscience, the first and only U.S. extension of the prestigious Max Planck Society, that may hold a stunning breakthrough in the fight to treat Alzheimer's disease.
Research published today in Biomed Central's open access journal Journal of Neuroinflammation suggests that chronic inflammation can predispose the brain to develop Alzheimer's disease.
The inexorable spread of Alzheimer's disease through the brain leaves dead neurons and forgotten thoughts in its wake.
Researchers from Boston University School of Medicine (BUSM) have identified a novel group of proteins that accumulate in the brains of patients with Alzheimer's disease.
An arsenal of Alzheimer's research revealed at the Society of Nuclear Medicine's 59th Annual Meeting indicates that beta-amyloid plaque in the brain not only is involved in the pathology of Alzheimer's disease but may also precede even mild cognitive decline.
Pathological aging (PA) is used to describe the brains of people which have Alzheimer's disease (AD)-like pathology but where the person showed no signs of cognitive impairment whilst they were alive.
- The governor of a province or people.